Loading…

Examining the Chirality, Conformation and Selective Kinase Inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)

Here, we examine the significance that stereochemistry plays within the clinically relevant Janus kinase 3 (Jak3) inhibitor 1 (CP-690,550). A synthesis of all four enantiopure stereoisomers of the drug was carried out and an examination of each compound revealed that only the enantiopure 3R,4R isome...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 2008-12, Vol.51 (24), p.8012-8018
Main Authors: Jiang, Jian-kang, Ghoreschi, Kamran, Deflorian, Francesca, Chen, Zhi, Perreira, Melissa, Pesu, Marko, Smith, Jeremy, Nguyen, Dac-Trung, Liu, Eric H, Leister, William, Costanzi, Stefano, O’Shea, John J, Thomas, Craig J
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a537t-31b5970c24059b3a967bb6ec396c48cd914bfb1553ac95c5f1ae3afacfbd3aac3
cites cdi_FETCH-LOGICAL-a537t-31b5970c24059b3a967bb6ec396c48cd914bfb1553ac95c5f1ae3afacfbd3aac3
container_end_page 8018
container_issue 24
container_start_page 8012
container_title Journal of medicinal chemistry
container_volume 51
creator Jiang, Jian-kang
Ghoreschi, Kamran
Deflorian, Francesca
Chen, Zhi
Perreira, Melissa
Pesu, Marko
Smith, Jeremy
Nguyen, Dac-Trung
Liu, Eric H
Leister, William
Costanzi, Stefano
O’Shea, John J
Thomas, Craig J
description Here, we examine the significance that stereochemistry plays within the clinically relevant Janus kinase 3 (Jak3) inhibitor 1 (CP-690,550). A synthesis of all four enantiopure stereoisomers of the drug was carried out and an examination of each compound revealed that only the enantiopure 3R,4R isomer was capable of blocking Stat5 phosphorylation (Jak3 dependent). Each compound was profiled across a panel of over 350 kinases, which revealed a high level of selectivity for the Jak family kinases for these related compounds. Each stereoisomer retained a degree of binding to Jak3 and Jak2 and the 3R,4S and 3S,4R stereoisomers were further revealed to have binding affinity for selected members of the STE7 and STE20 subfamily of kinases. Finally, an appraisal of the minimum energy conformation of each stereoisomer and molecular docking at Jak3 was performed in an effort to better understand each compounds selectivity and potency profiles.
doi_str_mv 10.1021/jm801142b
format article
fullrecord <record><control><sourceid>acs_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2660606</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>f70934955</sourcerecordid><originalsourceid>FETCH-LOGICAL-a537t-31b5970c24059b3a967bb6ec396c48cd914bfb1553ac95c5f1ae3afacfbd3aac3</originalsourceid><addsrcrecordid>eNptkc1u1DAQxyMEokvhwAugXJA20hr8mWwulVBUaEUr2m05IWRNHKfxktiRk1abh-Pd8HZXW5CQD_bM_Obv-YiitwR_IJiSj-tuiQnhtHwWzYigGPEl5s-jGcaUIppSdhS9GoY1xpgRyl5GRyTHgmUinUW_TzfQGWvsXTw2Oi4a46E147SIC2dr5zsYjbMx2Cq-0a1Wo3nQ8VdjYdDxuW1MaR7jro4Zms_ZasFXCeKo02MztSj4dq95dob6yXvXuh90wVD1M1imM5WxgZ7aZFuES3rTa__oJFtnyHcb13vXg9XWjN60Op4XVyjN8UIInLyOXtTQDvrN_j6Ovn8-vS3O0MW3L-fFpwsEoc0RMVKKPMOKcizykkGeZmWZasXyVPGlqnLCy7okQjBQuVCiJqAZ1KDqsmIAih1HJzvd_r7sdKW0HcOYZB9aAD9JB0b-G7GmkXfuQdI0xeEEgWQnoLwbBq_rQy7BcrtDedhhYN_9_dkTuV9aAN7vARgUtLUHq8xw4CjOl4JyHji048ww6s0hDv6XTLOgJG-vbuRKXF4X_PJaZk-6oAa5dvfehpn-p8A_qYnAKg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Examining the Chirality, Conformation and Selective Kinase Inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read &amp; Publish Agreement 2022-2024 (Reading list)</source><creator>Jiang, Jian-kang ; Ghoreschi, Kamran ; Deflorian, Francesca ; Chen, Zhi ; Perreira, Melissa ; Pesu, Marko ; Smith, Jeremy ; Nguyen, Dac-Trung ; Liu, Eric H ; Leister, William ; Costanzi, Stefano ; O’Shea, John J ; Thomas, Craig J</creator><creatorcontrib>Jiang, Jian-kang ; Ghoreschi, Kamran ; Deflorian, Francesca ; Chen, Zhi ; Perreira, Melissa ; Pesu, Marko ; Smith, Jeremy ; Nguyen, Dac-Trung ; Liu, Eric H ; Leister, William ; Costanzi, Stefano ; O’Shea, John J ; Thomas, Craig J</creatorcontrib><description>Here, we examine the significance that stereochemistry plays within the clinically relevant Janus kinase 3 (Jak3) inhibitor 1 (CP-690,550). A synthesis of all four enantiopure stereoisomers of the drug was carried out and an examination of each compound revealed that only the enantiopure 3R,4R isomer was capable of blocking Stat5 phosphorylation (Jak3 dependent). Each compound was profiled across a panel of over 350 kinases, which revealed a high level of selectivity for the Jak family kinases for these related compounds. Each stereoisomer retained a degree of binding to Jak3 and Jak2 and the 3R,4S and 3S,4R stereoisomers were further revealed to have binding affinity for selected members of the STE7 and STE20 subfamily of kinases. Finally, an appraisal of the minimum energy conformation of each stereoisomer and molecular docking at Jak3 was performed in an effort to better understand each compounds selectivity and potency profiles.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm801142b</identifier><identifier>PMID: 19053756</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Columbus, OH: American Chemical Society</publisher><subject>Biological and medical sciences ; Chemistry, Pharmaceutical - methods ; Drug Design ; Humans ; Hydrogen Bonding ; Immunomodulators ; Inhibitory Concentration 50 ; Janus Kinase 2 - chemistry ; Kinetics ; Medical sciences ; Models, Chemical ; Models, Molecular ; Molecular Conformation ; Monte Carlo Method ; Pharmacology. Drug treatments ; Piperidines ; Protein Binding ; Protein Kinase Inhibitors - chemical synthesis ; Protein Kinase Inhibitors - pharmacology ; Pyrimidines - chemical synthesis ; Pyrimidines - pharmacology ; Pyrroles - chemical synthesis ; Pyrroles - pharmacology ; Stereoisomerism</subject><ispartof>Journal of medicinal chemistry, 2008-12, Vol.51 (24), p.8012-8018</ispartof><rights>Copyright © 2008 U.S. Government</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a537t-31b5970c24059b3a967bb6ec396c48cd914bfb1553ac95c5f1ae3afacfbd3aac3</citedby><cites>FETCH-LOGICAL-a537t-31b5970c24059b3a967bb6ec396c48cd914bfb1553ac95c5f1ae3afacfbd3aac3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=20985244$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19053756$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jiang, Jian-kang</creatorcontrib><creatorcontrib>Ghoreschi, Kamran</creatorcontrib><creatorcontrib>Deflorian, Francesca</creatorcontrib><creatorcontrib>Chen, Zhi</creatorcontrib><creatorcontrib>Perreira, Melissa</creatorcontrib><creatorcontrib>Pesu, Marko</creatorcontrib><creatorcontrib>Smith, Jeremy</creatorcontrib><creatorcontrib>Nguyen, Dac-Trung</creatorcontrib><creatorcontrib>Liu, Eric H</creatorcontrib><creatorcontrib>Leister, William</creatorcontrib><creatorcontrib>Costanzi, Stefano</creatorcontrib><creatorcontrib>O’Shea, John J</creatorcontrib><creatorcontrib>Thomas, Craig J</creatorcontrib><title>Examining the Chirality, Conformation and Selective Kinase Inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>Here, we examine the significance that stereochemistry plays within the clinically relevant Janus kinase 3 (Jak3) inhibitor 1 (CP-690,550). A synthesis of all four enantiopure stereoisomers of the drug was carried out and an examination of each compound revealed that only the enantiopure 3R,4R isomer was capable of blocking Stat5 phosphorylation (Jak3 dependent). Each compound was profiled across a panel of over 350 kinases, which revealed a high level of selectivity for the Jak family kinases for these related compounds. Each stereoisomer retained a degree of binding to Jak3 and Jak2 and the 3R,4S and 3S,4R stereoisomers were further revealed to have binding affinity for selected members of the STE7 and STE20 subfamily of kinases. Finally, an appraisal of the minimum energy conformation of each stereoisomer and molecular docking at Jak3 was performed in an effort to better understand each compounds selectivity and potency profiles.</description><subject>Biological and medical sciences</subject><subject>Chemistry, Pharmaceutical - methods</subject><subject>Drug Design</subject><subject>Humans</subject><subject>Hydrogen Bonding</subject><subject>Immunomodulators</subject><subject>Inhibitory Concentration 50</subject><subject>Janus Kinase 2 - chemistry</subject><subject>Kinetics</subject><subject>Medical sciences</subject><subject>Models, Chemical</subject><subject>Models, Molecular</subject><subject>Molecular Conformation</subject><subject>Monte Carlo Method</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperidines</subject><subject>Protein Binding</subject><subject>Protein Kinase Inhibitors - chemical synthesis</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Pyrimidines - chemical synthesis</subject><subject>Pyrimidines - pharmacology</subject><subject>Pyrroles - chemical synthesis</subject><subject>Pyrroles - pharmacology</subject><subject>Stereoisomerism</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNptkc1u1DAQxyMEokvhwAugXJA20hr8mWwulVBUaEUr2m05IWRNHKfxktiRk1abh-Pd8HZXW5CQD_bM_Obv-YiitwR_IJiSj-tuiQnhtHwWzYigGPEl5s-jGcaUIppSdhS9GoY1xpgRyl5GRyTHgmUinUW_TzfQGWvsXTw2Oi4a46E147SIC2dr5zsYjbMx2Cq-0a1Wo3nQ8VdjYdDxuW1MaR7jro4Zms_ZasFXCeKo02MztSj4dq95dob6yXvXuh90wVD1M1imM5WxgZ7aZFuES3rTa__oJFtnyHcb13vXg9XWjN60Op4XVyjN8UIInLyOXtTQDvrN_j6Ovn8-vS3O0MW3L-fFpwsEoc0RMVKKPMOKcizykkGeZmWZasXyVPGlqnLCy7okQjBQuVCiJqAZ1KDqsmIAih1HJzvd_r7sdKW0HcOYZB9aAD9JB0b-G7GmkXfuQdI0xeEEgWQnoLwbBq_rQy7BcrtDedhhYN_9_dkTuV9aAN7vARgUtLUHq8xw4CjOl4JyHji048ww6s0hDv6XTLOgJG-vbuRKXF4X_PJaZk-6oAa5dvfehpn-p8A_qYnAKg</recordid><startdate>20081225</startdate><enddate>20081225</enddate><creator>Jiang, Jian-kang</creator><creator>Ghoreschi, Kamran</creator><creator>Deflorian, Francesca</creator><creator>Chen, Zhi</creator><creator>Perreira, Melissa</creator><creator>Pesu, Marko</creator><creator>Smith, Jeremy</creator><creator>Nguyen, Dac-Trung</creator><creator>Liu, Eric H</creator><creator>Leister, William</creator><creator>Costanzi, Stefano</creator><creator>O’Shea, John J</creator><creator>Thomas, Craig J</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20081225</creationdate><title>Examining the Chirality, Conformation and Selective Kinase Inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)</title><author>Jiang, Jian-kang ; Ghoreschi, Kamran ; Deflorian, Francesca ; Chen, Zhi ; Perreira, Melissa ; Pesu, Marko ; Smith, Jeremy ; Nguyen, Dac-Trung ; Liu, Eric H ; Leister, William ; Costanzi, Stefano ; O’Shea, John J ; Thomas, Craig J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a537t-31b5970c24059b3a967bb6ec396c48cd914bfb1553ac95c5f1ae3afacfbd3aac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Biological and medical sciences</topic><topic>Chemistry, Pharmaceutical - methods</topic><topic>Drug Design</topic><topic>Humans</topic><topic>Hydrogen Bonding</topic><topic>Immunomodulators</topic><topic>Inhibitory Concentration 50</topic><topic>Janus Kinase 2 - chemistry</topic><topic>Kinetics</topic><topic>Medical sciences</topic><topic>Models, Chemical</topic><topic>Models, Molecular</topic><topic>Molecular Conformation</topic><topic>Monte Carlo Method</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperidines</topic><topic>Protein Binding</topic><topic>Protein Kinase Inhibitors - chemical synthesis</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Pyrimidines - chemical synthesis</topic><topic>Pyrimidines - pharmacology</topic><topic>Pyrroles - chemical synthesis</topic><topic>Pyrroles - pharmacology</topic><topic>Stereoisomerism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jiang, Jian-kang</creatorcontrib><creatorcontrib>Ghoreschi, Kamran</creatorcontrib><creatorcontrib>Deflorian, Francesca</creatorcontrib><creatorcontrib>Chen, Zhi</creatorcontrib><creatorcontrib>Perreira, Melissa</creatorcontrib><creatorcontrib>Pesu, Marko</creatorcontrib><creatorcontrib>Smith, Jeremy</creatorcontrib><creatorcontrib>Nguyen, Dac-Trung</creatorcontrib><creatorcontrib>Liu, Eric H</creatorcontrib><creatorcontrib>Leister, William</creatorcontrib><creatorcontrib>Costanzi, Stefano</creatorcontrib><creatorcontrib>O’Shea, John J</creatorcontrib><creatorcontrib>Thomas, Craig J</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jiang, Jian-kang</au><au>Ghoreschi, Kamran</au><au>Deflorian, Francesca</au><au>Chen, Zhi</au><au>Perreira, Melissa</au><au>Pesu, Marko</au><au>Smith, Jeremy</au><au>Nguyen, Dac-Trung</au><au>Liu, Eric H</au><au>Leister, William</au><au>Costanzi, Stefano</au><au>O’Shea, John J</au><au>Thomas, Craig J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Examining the Chirality, Conformation and Selective Kinase Inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2008-12-25</date><risdate>2008</risdate><volume>51</volume><issue>24</issue><spage>8012</spage><epage>8018</epage><pages>8012-8018</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>Here, we examine the significance that stereochemistry plays within the clinically relevant Janus kinase 3 (Jak3) inhibitor 1 (CP-690,550). A synthesis of all four enantiopure stereoisomers of the drug was carried out and an examination of each compound revealed that only the enantiopure 3R,4R isomer was capable of blocking Stat5 phosphorylation (Jak3 dependent). Each compound was profiled across a panel of over 350 kinases, which revealed a high level of selectivity for the Jak family kinases for these related compounds. Each stereoisomer retained a degree of binding to Jak3 and Jak2 and the 3R,4S and 3S,4R stereoisomers were further revealed to have binding affinity for selected members of the STE7 and STE20 subfamily of kinases. Finally, an appraisal of the minimum energy conformation of each stereoisomer and molecular docking at Jak3 was performed in an effort to better understand each compounds selectivity and potency profiles.</abstract><cop>Columbus, OH</cop><pub>American Chemical Society</pub><pmid>19053756</pmid><doi>10.1021/jm801142b</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 2008-12, Vol.51 (24), p.8012-8018
issn 0022-2623
1520-4804
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2660606
source American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)
subjects Biological and medical sciences
Chemistry, Pharmaceutical - methods
Drug Design
Humans
Hydrogen Bonding
Immunomodulators
Inhibitory Concentration 50
Janus Kinase 2 - chemistry
Kinetics
Medical sciences
Models, Chemical
Models, Molecular
Molecular Conformation
Monte Carlo Method
Pharmacology. Drug treatments
Piperidines
Protein Binding
Protein Kinase Inhibitors - chemical synthesis
Protein Kinase Inhibitors - pharmacology
Pyrimidines - chemical synthesis
Pyrimidines - pharmacology
Pyrroles - chemical synthesis
Pyrroles - pharmacology
Stereoisomerism
title Examining the Chirality, Conformation and Selective Kinase Inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T15%3A16%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-acs_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Examining%20the%20Chirality,%20Conformation%20and%20Selective%20Kinase%20Inhibition%20of%203-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo%5B2,3-d%5Dpyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile%20(CP-690,550)&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Jiang,%20Jian-kang&rft.date=2008-12-25&rft.volume=51&rft.issue=24&rft.spage=8012&rft.epage=8018&rft.pages=8012-8018&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm801142b&rft_dat=%3Cacs_pubme%3Ef70934955%3C/acs_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a537t-31b5970c24059b3a967bb6ec396c48cd914bfb1553ac95c5f1ae3afacfbd3aac3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/19053756&rfr_iscdi=true